Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-α versus toxicity after melphalan alone

European Journal of Surgical Oncology

Volumn 27, Issue 4, 2001, Pages 390-395

  Vrouenraets, B C ^a   Eggermont, A M M ^b   Hart, A A M ^a   Klaase, J M ^a   Van Geel, A N ^b   Nieweg, O E ^a   Kroon, B B R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated limb perfusion; Melanoma; Melphalan; Toxicity; Tumour necrosis factor alpha

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; AMPUTATION; ARTICLE; CLINICAL TRIAL; COMPARTMENT SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GENDER; HUMAN; INCIDENCE; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TEMPERATURE MEASUREMENT;

EID: 0034937633     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2001.1124     Document Type: Article

References (31)

1. Thirty-five years of isolated limb perfusion for melanoma: Indications and results
2. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
3. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNFα), interferon-gamma (IFN-γ) and melphalan for stage III melanoma: Results of a multicentre pilot study
4. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study
5. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
6. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The multicenter European experience
7. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion
8. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan
9. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan
10. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs: The influence of acute regional toxic reactions
11. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma
12. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalating study
13. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion
14. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future
15. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial
16. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions
17. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics
18. Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities
19. Physiological and pharmacokinetics parameters in isolation perfusion of the limbs
20. Determinants of acute regional toxicity following isolated limb perfusion for melanoma
21. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma
22. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect
23. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation
24. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma
25. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion
26. Hyperthermia and chemotherapeutic agents
27. High dose recombinant tumour necrosis factor (rTNF) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer
28. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
29. Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion
30. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNFα), melphalan and interferon-gamma (IFNγ): Dose-finding experience at National Cancer Institute of Milan
31. Hyperthermic antiblastic perfusion with TNF-Alpha and L. Pam in patients with stage II, IIIA and IIIAB limb melanoma